NASDAQ:MDGL
Madrigal Pharmaceuticals, Inc. Stock News
$216.05
+5.46 (+2.59%)
At Close: May 02, 2024
Analyst Ratings for Madrigal Pharmaceuticals
03:04pm, Tuesday, 20'th Dec 2022 Benzinga
Madrigal Pharmaceuticals (NASDAQ:MDGL) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
1
3
0
0
Tesla To $285? Here Are 10 Other Price Target Changes For Tuesday
01:05pm, Tuesday, 20'th Dec 2022 Benzinga
Wells Fargo raised Ross Stores, Inc. (NASDAQ: ROST) price target from $120 to $135. Wells Fargo analyst Ike Boruchow maintained an Overweight rating on the stock. Ross Stores shares fell 0.9% to cl
Here's How An Options Trader Made $5.5 Million In One Day
01:05pm, Tuesday, 20'th Dec 2022 Benzinga
Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) shares rose sharply on Monday after the company announced positive topline results from the pivotal Phase 3 MAESTRO-NASH (fatty liver disease) biopsy trial
Madrigal (MDGL) Soars as Resmetirom Meets Goal in NASH Study
12:47pm, Tuesday, 20'th Dec 2022
Madrigal's (MDGL) phase III MAESTRO-NASH study evaluating resmetirom for treating nonalcoholic steatohepatitis and liver fibrosis meets both primary endpoints. Stock rises.
Tesla, Amazon, Apple, Madrigal, Walt Disney: Why These 5 Stocks Are Drawing Investors' Attention Today
12:47am, Tuesday, 20'th Dec 2022 Benzinga
Major Wall Street indices closed in the red on Monday as investor optimism on the much-anticipated Santa Claus rally began to fade over fears of recession gaining momentum. The Dow Jones index closed
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session
06:38pm, Monday, 19'th Dec 2022 Benzinga
Gainers
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial.
Axcella H
Why Madrigal Pharmaceuticals Stock Is Crushing It Today
04:50pm, Monday, 19'th Dec 2022 The Motley Fool
The company reported stellar late-stage clinical trial results for its experimental NASH (nonalcoholic steatohepatitis) drug.
Madrigal Pharmaceuticals, Cerevel Therapeutics And Some Other Big Stocks Moving Higher On Monday
03:49pm, Monday, 19'th Dec 2022 Benzinga
U.S. stocks traded mixed, with the Nasdaq Composite dropping around 90 points on Monday. Here are some big stocks recording gains in today’s session.
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
Tesla's Bouncing, but This Nasdaq Stock Tripled Monday Morning
03:32pm, Monday, 19'th Dec 2022 The Motley Fool
Good news can come in different forms.
Madrigal's Successful Late-Stage Trial Draws Options Bulls
03:15pm, Monday, 19'th Dec 2022
Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) is surging, last seen up 250.3% to trade at $223.50, after its experimental drug Resmetirom met the main goals of a late-stage study.
Why Madrigal Pharmaceuticals Stock Is Crushing It Today
11:50am, Monday, 19'th Dec 2022
The company reported stellar late-stage clinical trial results for its experimental NASH (nonalcoholic steatohepatitis) drug.
Madrigal Pharmaceuticals Stock Is Up 200% In One Day, Here's Why
10:53am, Monday, 19'th Dec 2022
Madrigal Pharmaceuticals announced positive results for a major clinical trial and shares are up more than 200% because of it.
Madrigal Pharmaceuticals shares soar on positive trial results for its NASH and liver fibrosis drug resmetirom
10:41am, Monday, 19'th Dec 2022
Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) shares have soared more than 250% after the biopharmaceutical company shared positive topline results from its pivotal Phase 3 MAESTRO-NASH biopsy clinical t
Why Is Madrigal Pharmaceuticals (MDGL) Stock Up 216% Today?
09:48am, Monday, 19'th Dec 2022
Madrigal Pharmaceuticals (NASDAQ: MDGL ) stock is rocketing higher on Monday after sharing results from its novel therapeutics for nonalcoholic steatohepatitis (NASH) treatment. The company reported p
Madrigal Pharma Stock Triples After Knocking NASH Study Out Of The Park
09:31am, Monday, 19'th Dec 2022
Madrigal scored a win in the particularly tricky NASH field on Monday after its study hit both its goals, sending MDGL stock flying. The post Madrigal Pharma Stock Triples After Knocking NASH Study Ou
